Analysis from continued follow-up of Phase 1/2 clinical trial data in Hunter syndrome (MPS II) reinforces potential for tividenofusp alfa (DNL310) to address full disease spectrumLaunch readiness ...

By bringing the long-standing and opposing views of quantum mechanics together to form a single cohesive theory, a research ...

A new publication from Opto-Electronic Advances; DOI 10.29026/oea.2026.250149, discusses a quarter-wave geometric-phase route ...

Centralized migration accelerates adaptation and drives parallel evolution, emphasizing the key influence of spatial organization on evolutionary dynamics across systems from pathogen transmission to ...

In a multicenter, phase 2 trial across 31 centers in 10 countries, apecotrep (BI 764198) reduced proteinuria by 40% over 12 ...

Not intended for the UK Apecotrep (BI 764198) is a potential first-in-class, oral, selective TRPC6 inhibitor being investigated as a novel, ...

ELPIS II top-line trial results are anticipated in the third quarter of 2026Laromestrocel Biological License Application (BLA) submission for ...

EDN announces this year’s winners of the Electronic Products Product of the Year Awards, selected by the editors.

South Africa’s consumer economy remains under sustained pressure. Disposable incomes are limited, GDP growth is muted, and margin pressure is intensifying across manufacturing and retail. There is no ...

ATI-2138 and ritlecitinib were assessed using a reversal model of murine alopecia universalis, the most severe AA phenotype.

The Hair Relaxer MDL is now focusing on bellwether cases to test claims that chemical relaxers cause cancers. After extensive discovery and expert analysis, the court will narrow the cases for trial, ...

Not intended for the UK Apecotrep (BI 764198) is a potential first-in-class, oral, selective TRPC6 inhibitor being investigated as a novel, targeted, non-immunosuppressive therapy in people with prima ...